Format

Send to

Choose Destination
Cytokine Growth Factor Rev. 2011 Apr;22(2):83-9. doi: 10.1016/j.cytogfr.2011.02.003. Epub 2011 Mar 5.

IL-6 signaling in autoimmunity, chronic inflammation and inflammation-associated cancer.

Author information

1
1st Medical Clinic, University of Erlangen-Nürnberg, Germany. markus.neurath@uk-erlangen.de

Abstract

IL-6 activates various cell types carrying the membrane bound IL-6R (classical IL-6 signaling) as well as IL-6R(-) gp130(+) cells via the soluble IL-6R (IL-6 trans-signaling). IL-6 signaling plays a pivotal role in controlling the differentiation and activation of T lymphocytes by inducing the Jak/STAT-3 and the Ras/Erk/C/EBP pathways. In particular, IL-6 modulates the resistance of T cells against apoptosis, induces activation of T helper cells and controls the balance between regulatory T cells and Th17 cells. Importantly, recent findings suggest that blockade of IL-6 signaling is effective in treating experimental models of autoimmune and chronic inflammatory diseases such as inflammatory bowel diseases, diabetes, multiple sclerosis, asthma and rheumatoid arthritis as well as models of inflammation-associated cancer. Thus, anti-IL-6/anti-IL-6R strategies emerge as promising novel approaches for therapy of inflammatory diseases in humans. In this review article, we discuss the latest findings on the role of IL-6 in experimental models of autoimmunity and cancer, as well as clinical perspectives.

PMID:
21377916
DOI:
10.1016/j.cytogfr.2011.02.003
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center